Clinical Trials of Adjuvant Trastuzumab

Randomized trial data from the advanced disease setting demonstrate that in women with HER2-overexpressing breast cancers, the combination of trastuzumab and chemotherapy — using either doxorubicin/cyclophosphamide or paclitaxel — results in improved progression-free and overall survival compared to the same chemotherapy given without trastuzumab. These encouraging results have led to a new generation of adjuvant trials evaluating a variety of chemotherapeutic regimens combined with trastuzumab and schedules of trastuzumab administration.

PHASE III RANDOMIZED STUDY OF ADJUVANT DOXORUBICIN, CYCLOPHOSPHAMIDE, AND DOCETAXEL WITH OR WITHOUT TRASTUZUMAB (HERECPTIN®) VERSUS TRASTUZUMAB, DOCETAXEL, AND EITHER CARBOPLATIN OR CISPLATIN IN WOMEN WITH HER2-NEU EXPRESSION NODE-NEGATIVE OPERABLE BREAST CANCER

Open Protocol
Protocol Id: BICG-006
Projected Accrual: 3,150 patients

Eligibility
- Node-negative or -positive, HER2-overexpressing (FISH-positive) breast cancer

ARM 1
- AC x 4 + docetaxel x 4

ARM 2
- AC x 4 + docetaxel x 4 + H (qw x 12 weeks) + H (qw x 24 weeks)

ARM 3
- (Docetaxel + C) x 6 + H (qw x 12 weeks) + H (qw x 24 weeks)

C=carboplatin or carboplatin + hydroxytrastuzumab

Study Contacts:
- Lineene Chag, Chair. Tel: 310-825-5268
- Jonsson Comprehensive Cancer Center, UCLA

SOURCE: NCI Physician Data Query, January 2003

PHASE III RANDOMIZED STUDY OF ADJUVANT DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL WITH OR WITHOUT TRASTUZUMAB (HERECPTIN®) IN WOMEN WITH HER2-NEU OVEREXPRESSING NODE-POSITIVE BREAST CANCER

Open Protocol
Protocol Id: BCIRG-006
Projected Accrual: 3,000 patients (1,000 per treatment arm)

Eligibility
- Node-positive, HER2-overexpressing breast cancer

ARM 1
- AC x 4 + T qw x 12

ARM 2
- AC x 4 + T qw x 12 + H qw x 52

T=paclitaxel; H=hydroxytrastuzumab

All ER/PR-positive patients receive tamoxifen or an aromatase inhibitor ≥ 5 years.

Patients may undergo radiotherapy at the completion of chemotherapy.

Study Contacts:
- Peter A Kaufman, Chair. Tel: 603-650-6700
- Cancer and Leukemia Group B
- Peter A Kaufman, Chair. Tel: 410-955-8489
- Eastern Cooperative Oncology Group
- Edith A Perez, Chair. Tel: 807-284-2111
- North Central Cancer Treatment Group
- Silvana Martino, Chair. Tel: 310-958-3961
- Southwest Oncology Group

SOURCE: NCI Physician Data Query, January 2003

PHASE III RANDOMIZED STUDY OF DOXORUBICIN, CYCLOPHOSPHAMIDE, AND DOCETAXEL WITH OR WITHOUT TRASTUZUMAB (HERECPTIN®) IN WOMEN WITH HER2-NEU EXPRESSING NODE-POSITIVE BREAST CANCER — Open Protocol
Protocol Id: NCI-098131, CLB-9099, E-N9831, SWOG-N9831
Projected Accrual: 3,000 patients (1,000 per treatment arm)

Eligibility
- Node-negative, HER2-overexpressing breast cancer

ARM 1
- AC x 4 + T qw x 12

ARM 2
- AC x 4 + T qw x 12 + H qw x 52

T=paclitaxel; H=trastuzumab

Study Contacts:
- Edward H Rimm, Chair. Tel: 859-323-8043
- National Surgical Adjuvant Breast and Bowel Project

SOURCE: NCI Physician Data Query, January 2003

INTERGROUP 9831 AND NSABP B-31 TRIALS

Intergroup trial 9831 (NCCTG-N9831) is an adjuvant study in patients with node-positive, HER2-positive breast cancer. We are also testing the question of whether trastuzumab should be used sequentially or concurrently with chemotherapy. NSABP B-31 has very similar eligibility criteria. Both adjuvant trastuzumab trials — NCCTG N9831 and NSABP B-31 — are carefully attending to cardiac tolerance. In our adjuvant trial, we have attempted to ameliorate the risk of cardiotoxicity by not using trastuzumab concurrently with anthracyclines and by limiting the dose of doxorubicin to 240 mg/m^2.

If someone uses adjuvant trastuzumab outside of a clinical trial setting, they’re essentially shooting in the dark. We do not yet understand how long this therapy should be given, what schedule should be used in combination with chemotherapy or the potential risks or benefits the patients may derive from such treatment.

—Edith A Perez, MD

NONANTHRACYCLINE COMBINATIONS IN THE ADJUVANT SETTING

The Breast Cancer International Research Group’s (BCIRG)’s trastuzumab adjuvant trial 006 is evaluating conventional chemotherapy strategies — four cycles of AC followed by four cycles of docetaxel in combination with trastuzumab. The arm we are most excited about is the docetaxel/cisplatin/trastuzumab arm. This is a nonanthracycline combination of synergistic drugs.

There is synergy between docetaxel/trastuzumab, as well as carboplatin/trastuzumab. In addition, we don’t have to worry as much about cardiotoxicity with that treatment.

—Mark Pegram, MD

ADJUVANT TRASTUZUMAB TRIALS

I feel strongly that trastuzumab should not be combined with anthracycline-based therapy in the adjuvant setting. Yet, two US cooperative groups have trials utilizing trastuzumab with anthracycline-based therapy. In patients with HER2-positive metastatic breast cancer, which is very aggressive and uniformly lethal with the old treatments, taking risks makes sense as long as the patient and physician are aware and patients are monitored. In the adjuvant setting, some patients may be cured by the initial radiation and surgery. Therefore, I think it is ill-advised to push women at risk for cardiac dysfunction, particularly if there are regimens that look superior in terms of their efficacy based on preclinical synergy.

—Dennis J Slamon, MD, PhD

CLINICAL USE OF ADJUVANT TRASTUZUMAB

I do not use adjuvant trastuzumab outside of a clinical trial, and there are adjuvant trials available at most large cancer centers. Trastuzumab is a very promising drug, which has generated tremendous enthusiasm, but there are concerns about long-term side effects. While all of us hope to bring the answers to our patients as soon as possible, we have tried very hard to limit the use of adjuvant trastuzumab to patients on a study.

—Harold J Burstein, MD, PhD

I have not used adjuvant trastuzumab in a nonprotocol setting. Our experience with bone marrow transplant taught us that we could not always trust our preconceived notions about what would work. We need to answer the questions regarding adjuvant trastuzumab quickly, so I have only been entering patients — even those with high risk (10 or more positive nodes or inflammatory disease) — on clinical trials.

—Melody Cle Obleigh, MD

Copyright © 2003 B.C. Decker, Inc. All rights reserved. Poster information is for educational purposes only and not to be used in patient care. Please see full prescribing information and protocols.

SELECT PUBLICATIONS


